SCHEMBL25683482

SCHEMBL25683482

CC(=O)CN(CCC(=O)OC(C)(C)C)C(=O)OCOP(=O)(OC(C)(C)C)OC(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25255776 0.90 — —
SCHEMBL25683350 0.88 CA14 (0.31) —
SCHEMBL25683324 0.87 — —
SCHEMBL25787628 0.86 CA12 (0.30) —
SCHEMBL25278203 0.86 CA14 (0.30) —
SCHEMBL25272070 0.85 SSTR4 (0.30) —
SCHEMBL25228532 0.83 CA14 (0.31) —
SCHEMBL25257371 0.83 CA14 (0.31) —
SCHEMBL25683609 0.83 — —
SCHEMBL25250137 0.83 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787825-B2 Therapeutic compounds for HIV virus infection GILEAD SCIENCES, INC. (US) 2023-10-17 — — US disclosed
US-20230203069-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. 2023-06-29 — — US disclosed
Send feedback